Albert Garcia-Romeu, Ph.D. is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine and a Guest Researcher at the National Institute on Drug Abuse Intramural Neuroimaging Research Branch, where he studies the effects of psychedelic drugs in humans, with a focus on psilocybin as an aid in the treatment of addiction.
February 3, 2020
Psychedelic advocates have long asserted that broader psychedelic use will lead to a more open, progressive society, but there are too many instances of right-wingers who have taken them for that to be true.
February 5, 2020
Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.
February 11, 2020
Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.
March 3, 2020
Our statement on a recent Chacruna article by Dr. Bia Labate.
March 4, 2020
Can psychedelic civil disobedience really stimulate systemic reorganization?
March 11, 2020
Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?
March 11, 2020
“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”
March 11, 2020
The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.
March 11, 2020
After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.
March 11, 2020
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.